Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Who’s to blame for the price Daraprim? It’s not who you think.

Brian C. Joondeph, MD
Meds
October 14, 2015
Share
Tweet
Share

Daraprim is a drug that no one ever heard of unless they are taking it. It is used to treat toxoplasmosis, a parasitic infection, has been around for decades, and is prescribed typically in patients with weakened immune systems, such as those with AIDS. Daraprim has been newsworthy because a small company, Turing Pharmaceuticals, recently purchased the drug from Impax Laboratories for $55 million, and promptly raised the price of Daraprim.

Originally $13.50 per pill, Turing raised the price to $750, sparking outrage over price gouging and taking advantage of sick patients. After the outcry, Turing will lower the price, but they have not disclosed by how much.

Is the Turing CEO a greedy businessman or an investor trying to recoup his investment and earn a profit? Should the free market determine drug prices or is there a role for government price controls?

Go back to 2003, the year Medicare Part D was created. Buried in the 1000+ page bill, which undoubtedly every member of Congress read and understood, was this dirty little secret: According to the law, Medicare itself is not allowed to negotiate drug prices with pharmaceutical companies. Was this known or debated at the time? The bill was rushed through Congress with a final vote at 3 a.m. How’s that for transparency?

Medicaid and Veterans Affairs are able to negotiate lower drug prices. As do foreign countries, which pay 50 percent less than we do for the same drugs. How could a bill like this pass through Congress? Easy. Lobbyists.

Credit former Congressman Billy Tauzin, R-La., for steering the bill through the House of Representatives, via arm twisting and a 3 a.m. vote. Rep. Tauzin was a long time Democrat, but he switched parties to maintain his seniority and power in Congress when Republicans took control in 1994. Eventually, he retired and became CEO of big pharma lobbying group PhRMA, earning a $2 million salary lobbying for the pharmaceutical industry. How’s that for a revolving door?

Passage of Medicare Part D more than paid for Mr. Tauzin’s salary. If Medicare had the same negotiating power as Medicaid, the Congressional Budget Office estimates, “It could save $116 billion over ten years,” money otherwise in the coffers of big pharma.

The argument is that pharmaceutical companies need profit for future research and development. That’s true. Bringing a new drug to market costs $2.5 billion. And takes 12 years on average with the odds of the new drug traveling from laboratory to pharmacy about 1 in 5,000. The counter argument is that most of the largest pharmaceutical companies spend more on marketing than on R&D. Meaning high drug prices are supporting TV commercials.

The result is that Medicare, and ultimately the taxpayers, pay whatever big pharma asks. That’s why medications used to treat macular degeneration cost $2,000 per month, consuming one-sixth of the Medicare Part B budget. For the patient with macular degeneration in both eyes, costs could reach $48,000 per year. Medicare happily pays the price set by big pharma. Other countries, on the other hand, negotiate prices down and pay approximately half of the U.S. cost.

Credit where credit is due. The Obama administration has asked Congress to authorize Medicare to directly negotiate with drug companies for some high-cost prescriptions. That will be a tough fight against the big pharma lobby.

Rather than focusing on a businessman buying a company and trying to make a profit, the attention should shift to the larger problem of Medicare’s non-negotiable prices, which everyone pays for through taxes and copays.

Brian C. Joondeph is an ophthalmologist and can be reached on Twitter @retinaldoctor. This article originally appeared in the Independent Journal.

Prev

Can we blame Martin Shkreli for succeeding in a system that we created?

October 14, 2015 Kevin 8
…
Next

Tips for patients to help ensure an accurate diagnosis

October 14, 2015 Kevin 114
…

ADVERTISEMENT

Tagged as: Medications

Post navigation

< Previous Post
Can we blame Martin Shkreli for succeeding in a system that we created?
Next Post >
Tips for patients to help ensure an accurate diagnosis

ADVERTISEMENT

More by Brian C. Joondeph, MD

  • Ophthalmology in the era of COVID-19

    Brian C. Joondeph, MD
  • An ophthalmologist analyzes Joe Biden’s red eye

    Brian C. Joondeph, MD
  • When medical science becomes fake news

    Brian C. Joondeph, MD

Related Posts

  • At the top of patients’ wish lists: price transparency

    Miranda Gill, MSN, RN
  • GOOP and Gwyneth: Blame mainstream media

    Arthur L. Caplan, PhD and Timothy Caulfield, LLM
  • Are generic drug price hikes media hype?

    Peter Ubel, MD
  • Drug price hikes sometimes have catastrophic effects on patients

    Zoe Tseng, MD and Suhas Gondi
  • Who’s really to blame for the obesity epidemic?

    Peter Ubel, MD
  • Blame the pain, not the opioids

    Angelika Byczkowski

More in Meds

  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • Most Popular

  • Past Week

    • Why taxing remittances harms families and global health care

      Dalia Saha, MD | Finance
    • How AI, animals, and ecosystems reveal a new kind of intelligence

      Fateh Entabi, MD | Tech
    • Why kratom addiction is the next public health crisis

      Muhamad Aly Rifai, MD | Meds
    • A physician employment agreement term that often tricks physicians

      Dennis Hursh, Esq | Finance
    • How just culture can reduce burnout and boost health care staff retention

      Olumuyiwa Bamgbade, MD | Physician
    • The hidden moral injury behind value-based health care

      Jonathan Bushman, DO | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Who gets to be well in America: Immigrant health is on the line

      Joshua Vasquez, MD | Policy
    • Why specialist pain clinics and addiction treatment services require strong primary care

      Olumuyiwa Bamgbade, MD | Conditions
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • How just culture can reduce burnout and boost health care staff retention

      Olumuyiwa Bamgbade, MD | Physician
    • Why embracing imperfection makes you truly unforgettable

      Osmund Agbo, MD | Physician
    • Affordable postpartum hemorrhage solutions every OB/GYN should know

      Frank I. Jackson, DO | Conditions
    • Why kratom addiction is the next public health crisis

      Muhamad Aly Rifai, MD | Meds
    • Why taxing remittances harms families and global health care

      Dalia Saha, MD | Finance
    • How are prostate exams done and why you shouldn’t avoid them

      Martina Ambardjieva, MD, PhD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why taxing remittances harms families and global health care

      Dalia Saha, MD | Finance
    • How AI, animals, and ecosystems reveal a new kind of intelligence

      Fateh Entabi, MD | Tech
    • Why kratom addiction is the next public health crisis

      Muhamad Aly Rifai, MD | Meds
    • A physician employment agreement term that often tricks physicians

      Dennis Hursh, Esq | Finance
    • How just culture can reduce burnout and boost health care staff retention

      Olumuyiwa Bamgbade, MD | Physician
    • The hidden moral injury behind value-based health care

      Jonathan Bushman, DO | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Who gets to be well in America: Immigrant health is on the line

      Joshua Vasquez, MD | Policy
    • Why specialist pain clinics and addiction treatment services require strong primary care

      Olumuyiwa Bamgbade, MD | Conditions
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • How just culture can reduce burnout and boost health care staff retention

      Olumuyiwa Bamgbade, MD | Physician
    • Why embracing imperfection makes you truly unforgettable

      Osmund Agbo, MD | Physician
    • Affordable postpartum hemorrhage solutions every OB/GYN should know

      Frank I. Jackson, DO | Conditions
    • Why kratom addiction is the next public health crisis

      Muhamad Aly Rifai, MD | Meds
    • Why taxing remittances harms families and global health care

      Dalia Saha, MD | Finance
    • How are prostate exams done and why you shouldn’t avoid them

      Martina Ambardjieva, MD, PhD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Who’s to blame for the price Daraprim? It’s not who you think.
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...